HK1175395A1 - 作為酶促活性調節物的應用 - Google Patents
作為酶促活性調節物的應用Info
- Publication number
- HK1175395A1 HK1175395A1 HK13101699.7A HK13101699A HK1175395A1 HK 1175395 A1 HK1175395 A1 HK 1175395A1 HK 13101699 A HK13101699 A HK 13101699A HK 1175395 A1 HK1175395 A1 HK 1175395A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hsp70
- enzymatic activity
- regulator
- bmp
- enzyme
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
- C12Y306/01003—Adenosine triphosphatase (3.6.1.3)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200800885 | 2008-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1175395A1 true HK1175395A1 (zh) | 2013-07-05 |
Family
ID=41124251
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11108223.9A HK1153678A1 (en) | 2008-06-26 | 2011-08-08 | Use of hsp70 as a regulator of enzymatic activity hsp70 |
HK13101699.7A HK1175395A1 (zh) | 2008-06-26 | 2013-02-06 | 作為酶促活性調節物的應用 |
HK14104008.6A HK1190644A1 (zh) | 2008-06-26 | 2014-04-25 | 作為酶促活性調節物的應用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11108223.9A HK1153678A1 (en) | 2008-06-26 | 2011-08-08 | Use of hsp70 as a regulator of enzymatic activity hsp70 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14104008.6A HK1190644A1 (zh) | 2008-06-26 | 2014-04-25 | 作為酶促活性調節物的應用 |
Country Status (18)
Country | Link |
---|---|
US (8) | US8540985B2 (zh) |
EP (6) | EP3031467B1 (zh) |
JP (2) | JP5616336B2 (zh) |
CN (2) | CN102123729B (zh) |
AT (1) | ATE552010T1 (zh) |
AU (1) | AU2009262670B2 (zh) |
BR (2) | BR122019024895B8 (zh) |
CA (2) | CA3004867C (zh) |
DK (4) | DK2318032T3 (zh) |
ES (4) | ES2555908T3 (zh) |
FI (1) | FI3578195T3 (zh) |
HK (3) | HK1153678A1 (zh) |
HU (1) | HUE025852T2 (zh) |
IL (2) | IL209979A (zh) |
PL (3) | PL2318032T3 (zh) |
PT (3) | PT2484371E (zh) |
RU (2) | RU2521672C2 (zh) |
WO (1) | WO2009155936A1 (zh) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006007560A2 (en) | 2004-07-01 | 2006-01-19 | University Of Pennsylvania | Targeted protein replacement for the treatment of lysosomal storage disorders |
ES2555908T3 (es) | 2008-06-26 | 2016-01-11 | Orphazyme Aps | Uso de Hsp70 como regulador de la actividad enzimática |
EP3626255A1 (en) | 2010-11-30 | 2020-03-25 | Orphazyme A/S | Methods for increasing intracellular activity of hsp70 |
JP6175431B2 (ja) * | 2011-06-20 | 2017-08-02 | アイカーン スクール オブ メディシン アット マウント サイナイ | ムコ多糖症およびその他のリソソーム障害に対する抗tnf療法 |
US20130090294A1 (en) * | 2011-06-28 | 2013-04-11 | Alternative Innovative Technologies Llc | Novel methods of use of hsp70 for increased performance or treatment of hsp70 related disorders |
WO2013006076A1 (en) * | 2011-07-04 | 2013-01-10 | New York University | The use of intranasally administered hsp70 protein to treat neurodegenerative diseases |
WO2013036875A1 (en) | 2011-09-07 | 2013-03-14 | Mount Sinai School Of Medicine | Ceramidase and cell differentiation |
HUP1100535A2 (en) * | 2011-09-26 | 2013-04-29 | Bracelia Invest Ltd | Pharmaceutical composition for enhancement of stem cell treatment |
HUP1100534A2 (en) * | 2011-09-26 | 2013-04-29 | Balazs Dr Hazay | Pharmaceutical composition for the treatment of muscle atrophy |
RU2685867C2 (ru) * | 2011-12-15 | 2019-04-23 | Алтернатив Инновейтив Текнолоджиз Ллц | Гибридные белки и белковые конъюгаты на основе белка теплового шока-70 (БТШ70) и способы их применения (варианты) |
EP2792137B1 (en) * | 2011-12-16 | 2015-09-30 | Li-Cor, Inc. | Luminescence imaging scanner |
JP2015515445A (ja) * | 2012-01-05 | 2015-05-28 | ビーチ ツリー ラボ、インコーポレイテッド | 低レベルの熱ショックタンパク質70(Hsp70)を投与することによって癌を処置する方法 |
US9045403B2 (en) | 2012-02-29 | 2015-06-02 | Coyote Pharmaceuticals, Inc. | Geranyl geranyl acetone (GGA) derivatives and compositions thereof |
US9526760B2 (en) * | 2012-05-21 | 2016-12-27 | The Regents Of The University Of Colorado, A Body Corporate | LEDGF peptides and formulations thereof for treatment of degenerative disorders |
US9492514B2 (en) | 2012-06-01 | 2016-11-15 | Icahn School Of Medicine At Mount Sinai | Ceramide levels in the treatment and prevention of infections |
JP6124046B2 (ja) * | 2012-07-06 | 2017-05-10 | 日立工機株式会社 | 背負式電源 |
US9119808B1 (en) | 2012-10-08 | 2015-09-01 | Coyote Pharmaceuticals, Inc. | Treating neurodegenerative diseases with GGA or a derivative thereof |
WO2014107686A1 (en) * | 2013-01-07 | 2014-07-10 | Coyote Pharmaceuticals, Inc. | Methods for treating neuron damage |
DK2968479T3 (da) | 2013-03-14 | 2019-08-12 | Icahn School Med Mount Sinai | Terapeutiske sure ceramidasesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf |
CN104237168B (zh) * | 2013-06-21 | 2017-12-12 | 国家纳米科学中心 | 一种检测液体样品中外囊体的方法 |
ES2881860T3 (es) | 2014-09-15 | 2021-11-30 | Orphazyme As | Formulación de arimoclomol |
US20160270458A1 (en) * | 2015-03-16 | 2016-09-22 | Mean Green Products, LLC | Cooling backpack apparatus |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
CA3014773A1 (en) | 2016-03-07 | 2017-09-14 | Cfgenome, Llc | Noninvasive molecular controls |
WO2017178029A1 (en) | 2016-04-13 | 2017-10-19 | Orphazyme Aps | Heat shock proteins and cholesterol homeostasis |
BR112018070653A2 (pt) * | 2016-04-29 | 2019-02-05 | Orphazyme As | ingrediente farmacêutico ativo, e, composição |
CN108026142B (zh) * | 2016-07-04 | 2022-07-08 | 艾凯奇(厦门)生物科技有限公司 | 孤儿核受体Nur77的配体及其用途 |
US20180099024A1 (en) * | 2016-10-06 | 2018-04-12 | Ramp Research, Llc | Methods, compositions, and kits involving alteration of the chaperone protein axis in a subject |
CN110753544A (zh) | 2017-05-24 | 2020-02-04 | 奥菲泽米有限公司 | 热激蛋白诱导物和额颞病况 |
US11801284B2 (en) | 2017-12-13 | 2023-10-31 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating motor neuron diseases |
KR20210015790A (ko) * | 2018-05-28 | 2021-02-10 | 오르파짐 에이/에스 | 질환의 바이오마커로서 pbmc 샘플에서 hsp70 단백질 수준 |
HUP1800298A1 (hu) | 2018-08-30 | 2020-05-28 | N Gene Res Laboratories Inc | Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére |
CN109867715B (zh) * | 2019-02-28 | 2022-06-17 | 中国科学院昆明植物研究所 | 一种叶绿体蛋白和ATPase酶活性突变体在提高植物抗逆性中的应用 |
US20230025256A1 (en) * | 2019-12-04 | 2023-01-26 | Simon Friedman | Protein blocking assembly and methods of making and using |
AU2021295437A1 (en) * | 2020-06-24 | 2023-02-02 | Zevra Denmark A/S | Arimoclomol for treating gaucher disease |
CN112301000B (zh) * | 2020-11-16 | 2023-04-25 | 吉林大学 | 一种能将应激信号转变为egfp荧光信号的报告细胞系 |
MX2023005954A (es) * | 2020-11-19 | 2023-09-04 | Zevra Denmark As | Procesos para preparar citrato de arimoclomol e intermediarios del mismo. |
WO2022115612A1 (en) * | 2020-11-25 | 2022-06-02 | Lysosomal and Rare Disorders Research and Treatment Center, Inc. | Inhibition of caspase pathway as a treatment for lysosomal storage disorders |
CN115192712B (zh) * | 2022-07-05 | 2023-08-01 | 四川大学华西第二医院 | Hsp抑制剂在制备胚胎神经系统畸形治疗的产品中的应用 |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989008661A1 (en) | 1988-03-18 | 1989-09-21 | The General Hospital Corporation | Human heat shock factor |
US5348945A (en) | 1990-04-06 | 1994-09-20 | Wake Forest University | Method of treatment with hsp70 |
DK0700445T3 (da) | 1993-06-04 | 2002-05-13 | Whitehead Biomedical Inst | Stressproteiner og anvendelser deraf |
ES2216009T3 (es) | 1994-03-21 | 2004-10-16 | Rijksuniversiteit Utrecht | Fragmentos peptidicos de proteinas de estres microbianas y composicion farmaceutica a base de estos para el tratamiento y la prevencion de enfermedades inflamatorias. |
US5985270A (en) | 1995-09-13 | 1999-11-16 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
US5837251A (en) | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
HU222994B1 (hu) | 1995-11-02 | 2004-01-28 | BIOREX Kutató és Fejlesztő Rt. | Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására |
US5962313A (en) | 1996-01-18 | 1999-10-05 | Avigen, Inc. | Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme |
WO1998012208A1 (en) | 1996-09-20 | 1998-03-26 | The University Of New Mexico | Heat shock protein complexes |
US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
US5830464A (en) | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
US6007821A (en) | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
ZA99499B (en) | 1998-01-23 | 1999-07-22 | Nat Jewish Medical Res Ct | Method for treating inflammatory diseases using heat shock proteins. |
AU757600B2 (en) | 1998-02-20 | 2003-02-27 | University Of Miami | Modified heat shock protein-antigenic peptide complex |
US7396681B1 (en) | 1998-03-27 | 2008-07-08 | Gabriele Multhoff | Application of Hsp70 proteins |
FR2777890B1 (fr) | 1998-04-22 | 2000-12-29 | Roussy Inst Gustave | Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer |
US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
US6475490B1 (en) | 1998-10-19 | 2002-11-05 | Fordham University | Compositions and methods for promoting tissue repair using heat shock proteins |
HU226617B1 (en) | 1998-12-14 | 2009-04-28 | Cytrx Corp | Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient |
HUP9900475D0 (en) | 1999-02-26 | 1999-04-28 | Biorex Kutato Fejlesztoe Kft | O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component |
CA2383213A1 (en) | 1999-09-10 | 2001-03-15 | Fordham University | Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins |
US20020039583A1 (en) | 1999-09-30 | 2002-04-04 | Subjeck John R. | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
US20030236300A1 (en) | 1999-10-27 | 2003-12-25 | Yale University | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
AU1582801A (en) | 1999-11-05 | 2001-06-06 | Board Of Regents Of The University Of Nebraska, The | Methods and compositions for protection against bovine herpesvirus |
US6964851B2 (en) | 1999-12-07 | 2005-11-15 | Stressgen Biotechnologies Corp. | Compositions and methods for detecting stress-inducible proteins |
GB9930443D0 (en) | 1999-12-22 | 2000-02-16 | King S College London | Novel use of heat shock proteins |
US20020127219A1 (en) | 1999-12-30 | 2002-09-12 | Okkels Jens Sigurd | Lysosomal enzymes and lysosomal enzyme activators |
US20010034042A1 (en) | 2000-01-20 | 2001-10-25 | Srivastava Pramod K. | Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents |
WO2001052877A1 (en) | 2000-01-21 | 2001-07-26 | University Of Connecticut Health Center | Compositions and methods to treat neurodegenerative disorders |
WO2001052890A1 (en) | 2000-01-21 | 2001-07-26 | University Of Connecticut Health Center | Heat shock/stress protein complexes as vaccines against neurodegenerative disorders |
HUP0001583A2 (hu) | 2000-04-18 | 2002-11-28 | BIOREX Kutató és Fejlesztő Rt. | Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké |
WO2001097829A2 (en) * | 2000-06-19 | 2001-12-27 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
AU2001277961A1 (en) | 2000-08-07 | 2002-02-18 | Antigenics, Llc | Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof |
US7517948B2 (en) | 2000-09-13 | 2009-04-14 | Multimmune Gmbh | Hsp70 peptide stimulating natural killer (NK) cell activity and uses thereof |
WO2002032923A2 (en) | 2000-09-15 | 2002-04-25 | University Of Connecticut Health Center | Improved formulations using heat shock/stress protein-peptide complexes |
US20020172682A1 (en) | 2000-10-20 | 2002-11-21 | University Of Connecticut Health Center | Using heat shock proteins to increase immune response |
IT1319277B1 (it) | 2000-10-24 | 2003-09-26 | Chiesi Farma Spa | Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer. |
AU2002239462A1 (en) | 2000-11-03 | 2002-06-03 | The Board Of Regents Of The University Of Nebraska | Compositions for protection against bovine viral diseases |
EP1209226A3 (en) | 2000-11-07 | 2002-06-05 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70) |
US20020142299A1 (en) | 2001-01-09 | 2002-10-03 | Davidson Beverly L. | PTD-modified proteins |
CA2438750A1 (en) * | 2001-02-20 | 2002-08-29 | Uab Research Foundation | Aminoglycoside treatment for lysosomal storage diseases |
RU2335295C2 (ru) | 2001-08-20 | 2008-10-10 | Юниверсити Оф Коннектикут Хелт Сентер | Способы получения композиций, включающих хитшоковые белки или альфа-2-макроглобулин, пригодных для лечения злокачественной опухоли и инфекционного заболевания |
EP1430076A2 (en) * | 2001-09-27 | 2004-06-23 | I.D.M. Immuno-Designed Molecules | Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same |
HU0103939D0 (en) | 2001-09-27 | 2001-11-28 | Biorex Kutato Fejlesztoe Kft | Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride |
GB0123756D0 (en) | 2001-10-03 | 2001-11-21 | King S College London | A novel chaperone-type of adjuvant for vaccination - Basic 1 |
US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
ITMI20012573A1 (it) | 2001-12-06 | 2003-06-06 | D B P Dev Biotechonologica L P | Gli acilsalicilati:una nuova classe di induttori di risposta heat shock |
JP2005514418A (ja) | 2002-01-11 | 2005-05-19 | ビオレックス クタトー エス フェイレストェー アールテー. | カルボキサミジン誘導体及び血管疾患の治療におけるそれらの使用 |
WO2003061684A2 (en) * | 2002-01-24 | 2003-07-31 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Tumour treatment compositions comprising hsp70 and tumour necrosis factor |
JP4632664B2 (ja) | 2002-02-13 | 2011-02-16 | デューク ユニバーシティ | 非ペプチド結合ストレス応答性ポリペプチドによる免疫応答の調節 |
IL148401A0 (en) | 2002-02-26 | 2002-09-12 | Hadasit Med Res Service | Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases |
US7658916B2 (en) | 2002-04-05 | 2010-02-09 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density |
EP1496599B1 (en) | 2002-04-12 | 2015-06-17 | Mitsubishi Denki Kabushiki Kaisha | Ac generator for vehicle |
US6984389B2 (en) | 2002-04-25 | 2006-01-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
RU2376029C2 (ru) | 2002-04-25 | 2009-12-20 | Юниверсити Оф Коннектикут Хелт Сентер | Применение белков теплового шока для улучшения терапевтического эффекта невакцинного лечебного воздействия |
JP2005533015A (ja) | 2002-05-02 | 2005-11-04 | ユニバーシティー オブ コネティカット ヘルス センター | 抗体療法の有効性を増強するための熱ショックタンパク質の使用 |
WO2004035602A2 (en) | 2002-05-02 | 2004-04-29 | University Of Connecticut Health Center | Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines |
GB0216414D0 (en) * | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
JP2006515165A (ja) | 2002-09-16 | 2006-05-25 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための新規組成物と方法 |
DK1625148T3 (da) | 2003-05-21 | 2013-01-14 | Biotech Tools Sa | Peptidkompleks |
US7244616B2 (en) | 2003-06-27 | 2007-07-17 | Bayer Pharmaceuticals Corporation | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
HUP0303584A3 (en) | 2003-10-30 | 2009-12-28 | Cytrx Corp | Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases |
EP2145896A3 (en) | 2003-11-12 | 2010-03-31 | Alfa Biogene International B.V. | Recovery of a heat shock protein |
EP1691819A4 (en) | 2003-11-25 | 2009-05-06 | Sinai School Medicine | THERAPY ON CHAPERON BASIS FOR NIEMANN PICK DISEASE |
EP2070947B1 (en) | 2003-12-05 | 2014-06-11 | multimmune GmbH | Therapeutic and diagnostic anti-Hsp70 antibodies |
US20060009520A1 (en) | 2004-05-12 | 2006-01-12 | Tall Alan R | Retinoid-based methods for altering macrophage cholesterol |
WO2005120558A2 (en) | 2004-05-25 | 2005-12-22 | University Of Connecticut Health Center | Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease |
JP2008523055A (ja) | 2004-12-10 | 2008-07-03 | ゼルニケ ビジネス サポート ビー.ヴィー. | 熱ショックタンパク質(hsp)および上室性不整脈 |
RU2283128C1 (ru) * | 2005-04-05 | 2006-09-10 | Сергей Викторович Луценко | Способ получения препарата белка из семейства стрессовых и препарат белка hsp70, полученный этим способом |
KR20080033242A (ko) | 2005-06-08 | 2008-04-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 리소좀 효소를 코딩하는 유전자의 돌연변이와 관련있는cns 질환의 치료 방법 |
WO2007041285A2 (en) | 2005-09-29 | 2007-04-12 | Viral Genetics, Inc. | Complexes of inactivated pepsin fraction and heat shock protein |
SI1945632T1 (sl) | 2005-11-08 | 2014-03-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto |
US20080039400A1 (en) * | 2006-01-24 | 2008-02-14 | Universiteit Utrecht Uu Holding B.V. | Treatment and prevention of inflammatory bowel diseases |
AU2007210159A1 (en) | 2006-01-26 | 2007-08-09 | Foldrx Pharmaceuticals, Inc. | Compounds and methods for modulating protein trafficking |
JP2009537179A (ja) | 2006-05-19 | 2009-10-29 | ザ スクリップス リサーチ インスティテュート | 蛋白質ミスフォールディングの処置 |
BRPI0713442A2 (pt) * | 2006-06-23 | 2012-03-06 | Amicus Therapeutics, Inc. | Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase |
DK2034839T3 (en) | 2006-06-30 | 2017-12-04 | Sloan-Kettering Institute For Cancer Res | TREATMENT OF NEURODEGENERATIVE DISEASES BY INHIBITION OF HSP90 |
WO2008021210A2 (en) | 2006-08-11 | 2008-02-21 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
JP2010503616A (ja) | 2006-08-29 | 2010-02-04 | フォルマンテク.・カンパニー, リミテッド | アポトーシスを抑制するための薬学的組成物および前記薬学的組成物をデリバーするための方法 |
MX2009005798A (es) * | 2006-12-01 | 2009-08-12 | Cytrx Corp | Recuperacion de apoplejia. |
EP2132309A4 (en) | 2007-02-23 | 2011-01-05 | Univ Florida | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES RELATED TO GLYCOGEN STORAGE |
WO2008112525A2 (en) | 2007-03-09 | 2008-09-18 | Link Medicine Corporation | Treatment of lysosomal storage diseases |
GB0705626D0 (en) | 2007-03-23 | 2007-05-02 | Royal Veterinary College | Method for enhancing sperm survival |
US20100168016A1 (en) | 2007-04-11 | 2010-07-01 | The Jackson Laboratory | Diagnosis and treatment of diseases caused by misfolded proteins |
MX2009011055A (es) | 2007-04-13 | 2010-01-13 | Amicus Therapeutics Inc | Tratamiento de la enfermedad de gaucher con chaperonas farmacologicas especificas y supervision del tratamiento utilizando marcadores sustitutos. |
JP5501956B2 (ja) | 2007-04-25 | 2014-05-28 | シトクロマ インコーポレイテッド | ビタミンd化合物およびワックス状担体を含有する制御放出性経口組成物 |
AU2008245578A1 (en) | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
TW200901958A (en) | 2007-05-04 | 2009-01-16 | Cytrx Corp | Diabetic wound healing |
GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
CN101801402B (zh) | 2007-07-06 | 2013-08-28 | 乌得勒支大学控股有限公司 | 炎性疾病和自身免疫疾病的治疗和预防 |
WO2009036349A1 (en) | 2007-09-12 | 2009-03-19 | Anaphore, Inc. | Hsp70-based treatment for autoimmune diseases |
US20100317690A1 (en) | 2007-11-21 | 2010-12-16 | Summit Corporation Plc | Treatment of protein folding disorders |
GB2466912B (en) | 2007-11-29 | 2012-01-04 | Hospital For Sick Children | Compositions and methods for treating lysosomal disorders |
KR20110007600A (ko) | 2008-01-30 | 2011-01-24 | 제론 코포레이션 | 세포배양 제품 및 스크리닝하는 방법 |
WO2009095452A1 (en) | 2008-01-31 | 2009-08-06 | Crystax Pharmaceuticals, S.L. | Crystal structure of the atpase domain of proteins of the hsp70 family |
CA2712593A1 (en) | 2008-02-01 | 2009-08-13 | The Scripps Research Institute | Methods for treating a condition characterized by dysfunction in protein homeostasis |
EP3272773B8 (en) | 2008-05-07 | 2020-11-18 | BioMarin Pharmaceutical Inc. | Lysosomal targeting peptides and uses thereof |
WO2009137796A2 (en) | 2008-05-08 | 2009-11-12 | Northwestern University | Method of regulating the heat shock response |
GB0809360D0 (en) * | 2008-05-22 | 2008-07-02 | Isis Innovation | Calcium modulation |
ES2555908T3 (es) | 2008-06-26 | 2016-01-11 | Orphazyme Aps | Uso de Hsp70 como regulador de la actividad enzimática |
WO2010015816A2 (en) | 2008-08-06 | 2010-02-11 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
WO2010022461A1 (en) | 2008-08-29 | 2010-03-04 | Children, Youth And Women's Health Service | Sulphated sugars to increase activity of sulphatases en lysosomal storage disorders |
JP2012504143A (ja) | 2008-09-29 | 2012-02-16 | バーテックス ファーマシューティカルズ インコーポレイテッド | 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の用量単位 |
WO2010053655A2 (en) | 2008-11-07 | 2010-05-14 | University Of Kansas | Therapeutic methods with withaferin a and analogs |
WO2010086418A1 (en) | 2009-01-29 | 2010-08-05 | Alfa Biogene International B.V. | Functional food product comprising heat shock protein or a hydrolysate thereof |
EP2218458A1 (en) | 2009-02-13 | 2010-08-18 | Fondazione Telethon | Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof |
EP2405888B1 (en) | 2009-03-10 | 2018-04-11 | Alfa Biogene International B.V. | Skin care product |
GB0906159D0 (en) | 2009-04-09 | 2009-05-20 | Summit Corp Plc | Drug combination for the treatment of proteostatic diseases |
ES2569514T3 (es) | 2009-06-17 | 2016-05-11 | Biomarin Pharmaceutical Inc. | Formulaciones para enzimas lisosómicas |
CA3120503A1 (en) | 2009-07-28 | 2011-02-10 | Takeda Pharmaceutical Company Limited | Compositions and methods for treating gaucher disease |
WO2011019763A2 (en) | 2009-08-10 | 2011-02-17 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for the treatment of krabbe and other neurodegenerative diseases |
US20110081428A1 (en) | 2009-09-16 | 2011-04-07 | The Buck Institute For Age Research | Use of thioflavin-like compounds to increase life span and/or health span |
JP5714019B2 (ja) | 2009-10-21 | 2015-05-07 | マイカーティス エヌ.ヴェ.MyCartis NV | 急性心不全の診断、予知及び/又は予後用バイオマーカー及びその使用 |
WO2011075686A2 (en) | 2009-12-18 | 2011-06-23 | Ventria Bioscience | Methods & compositions comprising heat shock proteins |
US20130209549A1 (en) | 2010-07-21 | 2013-08-15 | University Of South Florida | Materials and methods for treating neurodegenerative diseases |
EP3626255A1 (en) | 2010-11-30 | 2020-03-25 | Orphazyme A/S | Methods for increasing intracellular activity of hsp70 |
WO2013006076A1 (en) | 2011-07-04 | 2013-01-10 | New York University | The use of intranasally administered hsp70 protein to treat neurodegenerative diseases |
WO2013148333A1 (en) | 2012-03-28 | 2013-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Salicylic acid derivatives useful as glucocerebrosidase activators |
CN104902923A (zh) | 2012-11-05 | 2015-09-09 | 建新公司 | 用于治疗蛋白质病的组合物和方法 |
JP6571527B2 (ja) | 2012-11-21 | 2019-09-04 | ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドWuhan Yzy Biopharma Co., Ltd. | 二重特異性抗体 |
ES2881860T3 (es) | 2014-09-15 | 2021-11-30 | Orphazyme As | Formulación de arimoclomol |
-
2009
- 2009-06-26 ES ES13178928.1T patent/ES2555908T3/es active Active
- 2009-06-26 EP EP15185021.1A patent/EP3031467B1/en active Active
- 2009-06-26 RU RU2011102781/10A patent/RU2521672C2/ru active
- 2009-06-26 EP EP09768858A patent/EP2318032B1/en active Active
- 2009-06-26 CN CN200980131985.9A patent/CN102123729B/zh active Active
- 2009-06-26 EP EP13178928.1A patent/EP2659904B1/en active Active
- 2009-06-26 ES ES09768858T patent/ES2385735T3/es active Active
- 2009-06-26 CN CN201410713260.3A patent/CN104586846B/zh active Active
- 2009-06-26 DK DK09768858.4T patent/DK2318032T3/da active
- 2009-06-26 ES ES12161641.1T patent/ES2532083T3/es active Active
- 2009-06-26 EP EP23188945.2A patent/EP4285909A3/en active Pending
- 2009-06-26 DK DK12161641T patent/DK2484371T3/en active
- 2009-06-26 PT PT12161641T patent/PT2484371E/pt unknown
- 2009-06-26 EP EP12161641.1A patent/EP2484371B1/en active Active
- 2009-06-26 RU RU2014116069/10A patent/RU2571946C2/ru active
- 2009-06-26 PL PL09768858T patent/PL2318032T3/pl unknown
- 2009-06-26 HU HUE13178928A patent/HUE025852T2/en unknown
- 2009-06-26 DK DK13178928.1T patent/DK2659904T3/en active
- 2009-06-26 PL PL12161641T patent/PL2484371T3/pl unknown
- 2009-06-26 US US13/001,316 patent/US8540985B2/en active Active
- 2009-06-26 PT PT09768858T patent/PT2318032E/pt unknown
- 2009-06-26 AT AT09768858T patent/ATE552010T1/de active
- 2009-06-26 EP EP19160761.3A patent/EP3578195B1/en active Active
- 2009-06-26 DK DK19160761.3T patent/DK3578195T3/da active
- 2009-06-26 WO PCT/DK2009/050151 patent/WO2009155936A1/en active Application Filing
- 2009-06-26 BR BR122019024895A patent/BR122019024895B8/pt active IP Right Grant
- 2009-06-26 ES ES19160761T patent/ES2963910T3/es active Active
- 2009-06-26 BR BRPI0914684A patent/BRPI0914684C1/pt active IP Right Grant
- 2009-06-26 PT PT131789281T patent/PT2659904E/pt unknown
- 2009-06-26 CA CA3004867A patent/CA3004867C/en active Active
- 2009-06-26 JP JP2011515111A patent/JP5616336B2/ja active Active
- 2009-06-26 PL PL13178928T patent/PL2659904T3/pl unknown
- 2009-06-26 CA CA2728363A patent/CA2728363C/en active Active
- 2009-06-26 AU AU2009262670A patent/AU2009262670B2/en active Active
- 2009-06-26 FI FIEP19160761.3T patent/FI3578195T3/fi active
-
2010
- 2010-12-13 IL IL209979A patent/IL209979A/en active IP Right Grant
-
2011
- 2011-08-08 HK HK11108223.9A patent/HK1153678A1/xx unknown
-
2013
- 2013-02-06 HK HK13101699.7A patent/HK1175395A1/zh unknown
- 2013-08-19 US US13/969,944 patent/US9289472B2/en active Active
-
2014
- 2014-02-27 JP JP2014036108A patent/JP5860493B2/ja active Active
- 2014-04-25 HK HK14104008.6A patent/HK1190644A1/zh unknown
- 2014-07-14 US US14/330,235 patent/US20150004151A1/en not_active Abandoned
- 2014-10-27 IL IL235342A patent/IL235342B/en active IP Right Grant
-
2016
- 2016-02-19 US US15/048,483 patent/US9884058B2/en active Active
-
2017
- 2017-12-26 US US15/854,352 patent/US10543204B2/en active Active
-
2019
- 2019-11-27 US US16/698,277 patent/US11304941B2/en active Active
- 2019-11-27 US US16/698,092 patent/US11045460B2/en active Active
-
2022
- 2022-03-07 US US17/688,189 patent/US11938125B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL235342B (en) | Using hsp70 as a regulator of enzymatic activity | |
PH12017500930A1 (en) | Hsp90 inhibitor combinations | |
AU2009223508A8 (en) | Expression of catalase in Trichoderma | |
TW201129938A (en) | Personal mapping system | |
BR112012021933A2 (pt) | método para processamento de soluções de peroxigênio. | |
MY153871A (en) | Isoprene synthase variants for improved microbial production of isoprene | |
UA98629C2 (ru) | Соединения и способ модуляции киназ | |
EP2296693A4 (en) | COMPOUNDS FOR REINFORCING THE ANTIBACTERIAL EFFECT OF MYELOPEROXIDASE AND METHOD OF USE THEREOF | |
WO2005074655A3 (en) | Materials and method for promotion of nerve regeneration | |
WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
MY161843A (en) | Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency | |
GB201202561D0 (en) | Treatment of skin disorders | |
IL207943A0 (en) | Modulation of enzymatic structure, activity, and/or expression level | |
CA126489S (en) | Bottle | |
MX2010001187A (es) | Moduladores del receptor ccr9 y metodos para su uso. | |
MX2009009693A (es) | Metodos para activar irs-1 y akt. | |
MX2012004617A (es) | Metodos y composiciones para modular activacion de hepsina de proteina que estimula macrofago. | |
WO2009105507A3 (en) | Beloxepin, its enantiomers, and analogs thereof for the treatment of pain | |
IL192414A0 (en) | Siva ubiquitination and/or degradation-related activity and modulators thereof | |
MY151244A (en) | A gene encoding a protein having an ability to enhance a selenate reduction activity | |
UA35880U (ru) | Способ лечения острого токсико-аллергического гепатита | |
UA36090U (ru) | Способ лечения психопатических приступов-фаз у больных с органическим расстройством личности с агрессивным поведением | |
MX2014004027A (es) | Activadores de zimogeno. | |
AU321087S (en) | A bottle | |
MY143752A (en) | Regulation of gene expression in plants |